CSIMarket
 


Genocea Biosciences Inc   (GNCA)
Other Ticker:  
 
 

GNCA's Income from Cont. Operations Growth by Quarter and Year

Genocea Biosciences Inc 's Income from Cont. Operations results by quarter and year




GNCA Income from Cont. Operations (in millions $) FY 2022 FY 2021 FY 2020 FY 2019
IV Quarter December - -13.28 -14.99 -9.36
III Quarter September - -3.62 -4.56 -7.53
II Quarter June - -4.31 -11.32 -6.50
I Quarter March -15.98 -11.98 -12.85 -15.57
FY   -15.98 -33.19 -43.72 -38.96



GNCA Income from Cont. Operations first quarter 2022 Y/Y Growth Comment
Genocea Biosciences Inc in the first quarter 2022 recorded loss from continued operations of $ -15.98 millions.

According to the results reported in the first quarter 2022, Genocea Biosciences Inc achieved the best Income from Cont. Operations growth in Biotechnology & Pharmaceuticals industry. While Genocea Biosciences Inc ' s Income from Cont. Operations no change of % ranks overall at the positon no. in the first quarter 2022.




GNCA Income from Cont. Operations ( Y/Y Growth %) 2022
2021 2020 2019
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY   - - - -

Financial Statements
Genocea Biosciences Inc 's first quarter 2022 Income from Cont. Operations $ -15.98 millions GNCA's Income Statement
Genocea Biosciences Inc 's first quarter 2021 Income from Cont. Operations $ -11.98 millions Quarterly GNCA's Income Statement
New: More GNCA's historic Income from Cont. Operations Growth >>


GNCA Income from Cont. Operations (Quarter on Quarter Growth %)

2022
2021 2020 2019
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY (Year on Year)   - - - -




Income from Cont. Operations first quarter 2022 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #

Income from Cont. Operations Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 
Income from Cont. Operations first quarter 2022 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Income from Cont. Operations Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 

Income from Cont. Operations by Quarter for the Fiscal Years 2019, 2020, 2021, 2022

Genocea Biosciences Inc 's Q/Q Income from Cont. Operations Growth


Income from Cont. Operations Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


GNCA's I. Quarter Q/Q Income from Cont. Operations Comment
Current results of -15.98 millions by Genocea Biosciences Inc look even less good considering the -13.28 millions loss from continued operations a quarter before.

Within Biotechnology & Pharmaceuticals industry Genocea Biosciences Inc achieved highest sequential Income from Cont. Operations growth. While Genocea Biosciences Inc 's Income from Cont. Operations growth quarter on quarter, overall rank is .


Income from Cont. Operations Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Income from Cont. Operations Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Income from Cont. Operations Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


GNCA's I. Quarter Q/Q Income from Cont. Operations Comment
I. Quarter 2022 results of -15.98 millions by Genocea Biosciences Inc appear even less good considering the loss from continued operations -13.28 millions in the fourth quarter.

Within Biotechnology & Pharmaceuticals industry Genocea Biosciences Inc achieved highest sequential Income from Cont. Operations growth. While Genocea Biosciences Inc 's Income from Cont. Operations growth quarter on quarter, overall rank is .


Genocea Biosciences Inc 's 12 Months Income from Cont. Operations Growth Year on Year


Income from Cont. Operations TTM Growth

12 Months Ending
(Mar 31 2022)
12 Months Ending
(Dec 31 2021)
12 Months Ending
(Sep 30 2021)
12 Months Ending
(Jun 30 2021)
12 Months Ending
(Mar 31 2021)
Cumulative Income from Cont. Operations 12 Months Ending $ -37.19 $ -33.20 $ -34.90 $ -35.83 $ -42.84
Y / Y Income from Cont. Operations Growth (TTM) - - - - -
Year on Year Income from Cont. Operations Growth Overall Ranking # # # # #
Seqeuential Income from Cont. Operations Change (TTM) - - - - -
Seq. Income from Cont. Operations Growth (TTM) Overall Ranking # # # # #




Cumulative Income from Cont. Operations growth Comment


Genocea Biosciences Inc achieved highest trailing twelve month year on year Income from Cont. Operations growth. While overall Income from Cont. Operations growth ranking, remained unchanged compare to the previous quarter at no. .

Income from Cont. Operations TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 

Income from Cont. Operations TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #

Income from Cont. Operations TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Income from Cont. Operations TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative Income from Cont. Operations growth Comment


Genocea Biosciences Inc achieved highest trailing twelve month year on year Income from Cont. Operations growth. While overall Income from Cont. Operations growth ranking, remained unchanged compare to the previous quarter at no. .

Income from Cont. Operations TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 


Income from Cont. Operations TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #

Income from Cont. Operations TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Income from Cont. Operations TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #




Other Income from Cont. Operations Growth
Biotechnology & Pharmaceuticals Industry Income from Cont. Operations Growth Trends and Statistics
Healthcare Sector Income from Cont. Operations Growth Statistics
Income from Cont. Operations Growth Trends for overall market
GNCA's Income from Cont. Operations Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Income from Cont. Operations Growth
Lowest Ranking Income from Cont. Operations Growth
Income from Cont. Operations Growth for GNCA's Competitors
Income from Cont. Operations Growth for Genocea Biosciences Inc 's Suppliers
Income from Cont. Operations Growth for GNCA's Customers

You may also want to know
GNCA's Annual Growth Rates GNCA's Profitability Ratios GNCA's Asset Turnover Ratio GNCA's Dividend Growth
GNCA's Roe GNCA's Valuation Ratios GNCA's Financial Strength Ratios GNCA's Dividend Payout Ratio
GNCA's Roa GNCA's Inventory Turnover Ratio GNCA's Growth Rates GNCA's Dividend Comparisons



Companies with similar Income from Cont. Operations no change for the quarter ending Mar 31 2022 within Healthcare SectorY/Y Change %Income from Cont. Operations for the quarter ending Mar 31 2022
Conmed Corporation51.88%$ 51.876 millions
Becton Dickinson And Company51.33%$ 51.333 millions
Iqvia Holdings Inc 49.77%$ 49.770 millions
Charles River Laboratories International inc 48.94%$ 48.942 millions
Co diagnostics Inc 48.31%$ 48.305 millions
Phibro Animal Health Corporation45.46%$ 45.457 millions
Abcellera Biologics Inc 43.81%$ 43.808 millions
Medpace Holdings Inc 41.58%$ 41.576 millions
Eli Lilly And Company40.40%$ 40.404 millions
Abbott Laboratories36.48%$ 36.475 millions
Merck and Co Inc 35.37%$ 35.374 millions
Bio techne Corp32.47%$ 32.470 millions
The Pennant Group Inc 26.83%$ 26.835 millions
Abbvie inc 26.39%$ 26.385 millions
Tenet Healthcare Corp25.68%$ 25.676 millions
Glucotrack Inc 20.91%$ 20.907 millions
Syneos Health Inc 19.24%$ 19.244 millions
Utah Medical Products Inc16.87%$ 16.865 millions
Ufp Technologies Inc 16.69%$ 16.695 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com